Yingxi Intelligent announces a global pipeline licensing and AI drug development collaboration with Eli Lilly

People’s Financial News, March 29 - Insilico Medicine announced on the Hong Kong Stock Exchange that it has reached a licensing and drug development collaboration with Eli Lilly and Company (“Lilly”). The two parties will utilize Insilico’s AI drug discovery capabilities to accelerate the discovery and development of novel therapies across multiple therapeutic areas. Under the terms of this collaboration agreement, Lilly will receive a global exclusive license to develop, manufacture, and commercialize a new oral therapy targeting specific indications that are currently in the preclinical development stage and have the potential to become “best-in-class.” Furthermore, by combining Insilico’s advanced Pharma.AI platform capabilities with Lilly’s deep expertise in research and development and disease areas, Insilico and Lilly will also engage in multiple R&D collaborations centered around the targets selected by Lilly. According to the relevant terms of the agreement, Insilico will be eligible to receive a $115 million upfront payment, and will receive further payments upon achieving development, regulatory, and commercialization milestones, bringing the total value of the deal to approximately $2.75 billion; additionally, Insilico will receive tiered royalties based on future sales.